ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial
March 11, 2021Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries. -
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
November 06, 2020The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 ...
Pharma Sources Insight January 2025
